Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study: response to Delea et al.

Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM, Ferrara A, Selby JV.

Diabetes Care. 2004 Mar;27(3):850-1; author reply 852-3. No abstract available.

PMID:
14988326
2.

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study.

Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS.

Diabetes Care. 2003 Nov;26(11):2983-9.

PMID:
14578227
3.

Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes.

Toprani A, Fonseca V.

Diabetes Obes Metab. 2011 Mar;13(3):276-80. doi: 10.1111/j.1463-1326.2010.01348.x. Erratum in: Diabetes Obes Metab. 2012 Apr;14(4):386.

PMID:
21205120
5.

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Acta Diabetol. 2009 Jun;46(2):145-54. doi: 10.1007/s00592-008-0090-3. Epub 2009 Feb 5.

PMID:
19194648
6.

Type 2 diabetes mellitus and heart failure.

Choy CK, Rodgers JE, Nappi JM, Haines ST.

Pharmacotherapy. 2008 Feb;28(2):170-92. doi: 10.1592/phco.28.2.170. Review.

PMID:
18225964
7.

Thiazolidinediones in patients with diabetes mellitus and heart failure : implications of emerging data.

Macfarlane DP, Fisher M.

Am J Cardiovasc Drugs. 2006;6(5):297-304. Review.

PMID:
17083264
8.

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.

Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM.

Circulation. 2005 Feb 8;111(5):583-90.

9.
10.

The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.

Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD.

Pharmacoepidemiol Drug Saf. 2007 May;16(5):504-12.

PMID:
17245800
11.

Risk of heart failure in patients with recent-onset type 2 diabetes: population-based cohort study.

Leung AA, Eurich DT, Lamb DA, Majumdar SR, Johnson JA, Blackburn DF, McAlister FA.

J Card Fail. 2009 Mar;15(2):152-7. doi: 10.1016/j.cardfail.2008.10.004. Epub 2008 Nov 28.

PMID:
19254675
12.

Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure.

Granberry MC, Hawkins JB, Franks AM.

Am J Health Syst Pharm. 2007 May 1;64(9):931-6. Review.

PMID:
17468147
13.

Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.

Patel RR.

Cardiol Rev. 2009 May-Jun;17(3):132-5. doi: 10.1097/CRD.0b013e31819faab2. Review.

PMID:
19384087
14.

Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting.

Maru S, Koch GG, Stender M, Clark D, Gibowski L, Petri H, White AD, Simpson RJ Jr.

Diabetes Care. 2005 Jan;28(1):20-6.

PMID:
15616228
15.

[Heart failure with thiazolidinedione treatment: what do we know today?].

Erdmann E.

Dtsch Med Wochenschr. 2009 Jan;134(4):154-8. doi: 10.1055/s-0028-1123973. Epub 2009 Jan 15. Review. German.

PMID:
19148858
16.

Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.

Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB.

Pharmacotherapy. 2006 Feb;26(2):168-81. Review.

PMID:
16466323
17.

Thiazolidinediones and cardiovascular outcomes in type 2 diabetes.

Singh S, Furberg CD.

Heart. 2009 Jan;95(1):1-3. doi: 10.1136/hrt.2008.155507. Epub 2008 Aug 27. No abstract available.

PMID:
18753156
18.

The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure.

Aguilar D, Bozkurt B, Pritchett A, Petersen NJ, Deswal A.

J Am Coll Cardiol. 2007 Jul 3;50(1):32-6. Epub 2007 Jun 18.

19.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
20.

Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.

Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, Lang NP.

J Clin Oncol. 2007 Apr 20;25(12):1476-81.

Items per page

Supplemental Content

Write to the Help Desk